ESTRO 36 Abstract Book

779 / 1096

S763 ESTRO 36
_______________________________________________________________________________________________
(10.2%) patients developed acute toxicity >2, while 5
patients (6.4%) developed late toxicity >2.
Conclusion
SBRT is a safe and effective management option for the
control of oligometastatic disease . This therapeutic
approach can have an important role in delaying disease
progression. Toxicity seems to be moderate in most cases
EP-1429 maintaining efficacy of low-dose radiotherapy
on pain and function in degenerative skeletal diseases
B. Alvarez 1, A. Montero1, E. Sanchez1, R. Ciervide 1, F.
Aramburu2, M. Hernández 1, M. López1, S. Rodríguez2, M.
Valero2, J.J. Valero1, M. García-Aranda1, E. Calvo2, O.
Hernando1, X. Chen1, R. Alonso3, P. García de la Peña2,
C. Rubio1
1 Hospital universitario hm madrid sanchinarro, Radiation
Oncology, Madrid, Spain
2 Hospital universitario hm Madrid sanchinarro,
rheumatology, Madrid, Spain
3 Hospital universitario hm puerta del sur, radiation
oncology, madrid, Spain
Purpose or Objective
to evaluate feasibility and duration of response induced by
low dose radiotherapy (RT) in patients with painful
degenerative diseases comprising enthesiopathies or
osteoarthritis refractory to any conventional treatment.
Material and Methods
From April 2015 to October 2016, 53 patients with painful
skeletal disorders of different locations were treated; 16
(30%) patients were monitored for more than six months.
The pain was evaluated before radiotherapy and 6 weeks
after treatment according to the visual analogue pain
scale (VAS) and the requirements of daily oral analgesic
intake.
All patients underwent CT simulation and were treated in
a conventional linac. PTV included the affected joint and
periarticular soft tissues. Prescribed dose to the PTV was
6 Gy at 1Gy/fraction each two days. If needed, a second
course similar to the previous was delivered after 6-8
weeks.
Results
All 16 patients were women and the average age was 68
years old. Five treatments were located on hands, 4 on
knees, and the 6 remaining at diverse joints. A second
course of 6 Gy was required by 50% of patients. Pre-RT
median pain score according to VAS was 7.5 (range 4-9);
median post-RT pain according to VAS was 1 (range 0-4).
There was a reduction of more than 4 points in all
patients. Eighty-one per cent of patients reported
subjective clinical improvement of their joint pain; 38% of
patients reduced their analgesic intake, 6% maintained the
same and 31% discontinued oral analgesic.
Conclusion
Our results support the efficacy and safety of low-dose
anti-inflammatory radiotherapy as an alternative
treatment for painful osteoarticular degenerative
diseases. Pain response and functional improvement
maintained for long time in a substantial proportion of
patients on follow-up.
EP-1430 Venous thromboembolism in radiation
oncology: retrospective trial
M. Cherkashin1, N. Berezina1, N. Vorobyov1, E. Pinelis2
1 Dr Berezin Medical Center, Oncology, Saint-Petersburg,
Russian Federation
2 Albert Einstein College of Medicine, Respiratory Care,
New York, USA
Purpose or Objective
Venous thromboembolism (VTE) prevention in oncology
patients during external beam radiation therapy (RT) in
outpatient setting is the challenging question. There is no
clear statement from international societies (ASCO, ESMO,
ACCP) and os far it is unclear if RT is an independent risk
factor for VTE. Last years a couple of published trials have
reported some VTE cases in this group of patients, but lack
of evidence is the common problem. The objective of this
study is the clear assessment of VTE incidence in these
patients
Material and Methods
In retrospective analysis 3280 patients' medical records
were included (1612 with RT and 1668 with
chemotherapy). Inclusion criteria were: RT in outpatient
setting, chemotherapy in outpatient setting and exclusion
criteria: combined radiochemotherapy, hospitalzation,
central venous catheter, palliative treatment. 360
patients were selected for the final analysis and were
stratified in 3 groups: group I (n=120) 3D-conformal RT for
brain tumors or brain metastasis; group II (n=120) RT for
body tumors (abdominal, retroabdominal, pelvic, chest,
breast); group III (n=120) was control –brain and body
tumors on chemotherapy. Mean fraction numbers were 25
(11 - 32), mean total dose – 52 Gy (22 - 66). VTE
assessment based on clinical data, venous ultrasound
examination (US) and chest CT. Statistical analysis was
performed by OpenEpi, Version 3 software pack.
Results
Deep vein thrombosis (DVT) was detected in 7 cases (5.8%)
in group I, 2 cases in group II and 1 case in control group.
VTE patients has a different tumors (right parietal area
astrocytoma, brain trunk tumor, skull basis cancer, rectal
cancer, breast cancer). 3 patients were available for long-
term outcomes assessment (12 months after radiation
therapy). During 1-year period we haven’t detected
thrombosis recurrence. Post thrombotic disease had
developed but without severe venous insufficiency. One
patient on 11th follow-up month was exposed with
repeated course of RT without any complications. The
difference between VTE incidence for group I and group III
characterized by statistical significance (p=0.018). Risk
difference for these groups was 5% (p<0.05).
Conclusion
Based on study results we suggest that external beam
radiation therapy is potentially an independent risk factor
for venous thromboembolism development even in
outpatient settings. High degree of clinical suspicion and
aggressive diagnostic work-up in case of suspicion is
necessary. In our opinion VTE prevention with low
molecular weight or unfractionated heparin should be
considered in selected patients at least during active
radiation therapy
EP-1431 Acute toxicity in deep loco-regional
hyperthermia
E. Burchardt 1, A. Roszak2, B. Urbañski3, A. Nowak3
1Greater Poland Cancer Centre, Department of
Oncological Gynecology and Radiotherapy, Poznan,
Poland
2Greater Poland Cancer Centre, oncological gynecology
and radiotherapy, Poznań, Poland
3Greater Poland Cancer Centre, Department of
Oncological Gynecology and Radiotherapy, Poznań,
Poland
Purpose or Objective
A series of phase III trials demonstrated the clinical effect
of hyperthermia. In January 2016 a new device for deep
regional hyperthermia was installed in our cancer centre.
The aim of this study was to assess tolerance and acute
toxicity of loco-regional hyperthermia given during
oncological treatment.
Material and Methods
101 patients (pts) were evaluated during treatment in the
period of time from January till September 2016. 45 pts